Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.
Eric M. Horwitz, MD, Inducted into Inaugural Class of Fellows of the American Brachytherapy Society
PHILADELPHIA (February 21, 2017)— Eric M. Horwitz, MD, chair of the Department of Radiation Oncology at Fox Chase Cancer Center, has been selected by the American Brachytherapy Society (ABS) as an inaugural ABS Fellow. He will be formally recognized at the ABS 2017 Annual Conference in Boston in April.
In nearly 20 years at Fox Chase he has guided the growth of the Radiation Oncology Department in both size and impact. Under Horwitz’s leadership, Fox Chase has notably expanded its radiation oncology treatment options and patient volumes. His achievements include implementation of an MRI treatment simulator into prostate cancer treatment, and making Fox Chase the first in the northeastern United States to offer High Dose Rate (HDR) brachytherapy implants to men with prostate cancer. Since 2009 Horwitz has held the Gerald E. Hanks Chair in Radiation Oncology.
Horwitz is a past president and board chair of ABS, and he currently serves on the editorial board of its journal, Brachytherapy.
“This is a tribute to Dr. Horwitz’s fine career and his contributions to the field of brachytherapy and to the ABS,” said Steven Frank, MD, president of the American Brachytherapy Society.
Horwitz is one of 12 fellows in the inaugural class. His prior honors include appearing in Philadelphia magazine’s Top Docs consecutively for more than a decade, and he was most recently recognized in America’s Top Doctors® 2016.
Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.
For more information, call 888-369-2427